Therapy Areas: Hereditary Disorders
US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months
2 September 2022 - - The US Food and Drug Administration approved expanded use of Orkambi (lumacaftor/ivacaftor) to include children with cystic fibrosis ages 12 to
Login
Username:

Password:


Related Headlines